SIBN
NEUTRAL
$14.09
Live
SI-BONE, Inc. · NASDAQ
Target $25.5
(+81.0%)
$12.15
52W Range
$21.89
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 19, 2026
Market cap
$622.29M
P/E
N/A
ROE
-11.0%
Profit margin
-9.4%
Debt/Equity
0.21
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
80%
SIBN presents a classic high-risk, high-reward growth profile, characterized by a stable Piotroski F-Score of 4/9 and exceptional liquidity. While the company remains unprofitable with negative net margins, it demonstrates a strong trajectory of narrowing losses and consistent earnings beats (average surprise 40.87%). The balance sheet is fortress-like with a current ratio of 8.55 and low debt, but this is offset by heavy insider selling and a long-term bearish price trend. The disconnect between the 'Strong Buy' analyst consensus and the bearish insider sentiment suggests a speculative environment.
Key Strengths
Exceptional liquidity with a Current Ratio of 8.55 and Quick Ratio of 7.05
Very strong Gross Margin of 79.57%, indicating high product value and pricing power
Consistent track record of beating earnings estimates (3 of last 4 quarters)
Strong YoY EPS growth of 63.6% as the company narrows its losses
Low leverage with a Debt/Equity ratio of 0.21
Key Risks
Negative Profit Margin (-9.41%) and Operating Margin (-4.37%)
Heavy insider selling (15 sell transactions, 0 buys) totaling $4.37M
Long-term price erosion with a 5-year change of -59.4%
Speculative nature of the business as explicitly cautioned in the 10-K filing
Bearish technical trend (0/100 score)
AI Fair Value Estimate
Based on comprehensive analysis
$20.5
+45.5% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
43
Moderate
40
75
30
70
0
AI Verdict
Speculative Growth
Key drivers: Strong balance sheet liquidity, Improving EPS trajectory, Heavy insider divestment, Lack of current profitability
Confidence
85%
Value
40/100
Ref P/E N/A, P/S 3.10, Graham Number None
Positives
- Reasonable Price/Sales ratio of 3.10
Watchpoints
- No P/E due to negative earnings
- Price/Book of 3.46 is elevated for a non-profitable firm
Future
75/100
Ref Growth rates and Analyst Targets
Positives
- 15% YoY Revenue growth
- 63.6% EPS growth
- High analyst target price of $25.50
Watchpoints
- Forward P/E remains negative
Past
30/100
Ref Historical price performance
Positives
- Recent 1-month recovery (+9.7%)
Watchpoints
- Severe 5-year decline (-59.4%)
- 3-year decline (-30.9%)
Health
70/100
Ref Piotroski F-Score and Liquidity Ratios
Positives
- Piotroski F-Score 4/9 (Stable)
- Extremely low Debt/Equity (0.21)
- Massive cash runway (Current Ratio 8.55)
Watchpoints
- Negative ROE and ROA
Dividend
0/100
Ref Yield N/A
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 Dividend Strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$14.09
Analyst Target
$25.5
Upside/Downside
+81.0%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for SIBN and closest competitors.
Updated 2026-04-17
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
SIBN
SI-BONE, Inc.
Primary
|
-59.4% | -30.9% | +1.7% | -4.4% | +9.7% | +9.7% |
|
AVNS
Avanos Medical, Inc.
Peer
|
-72.6% | -56.0% | -17.1% | +9.0% | +14.8% | +6.1% |
|
OCGN
Ocugen, Inc.
Peer
|
-66.3% | +137.8% | +179.0% | +16.8% | -16.3% | +4.8% |
|
RIGL
Rigel Pharmaceuticals, Inc.
Peer
|
-6.8% | +165.8% | +92.5% | +16.1% | +27.5% | +11.1% |
|
ESPR
Esperion Therapeutics, Inc.
Peer
|
-91.3% | +70.1% | +119.8% | -9.3% | -23.4% | -10.7% |
SIB
SI-BONE, Inc.
Primary
5Y
-59.4%
3Y
-30.9%
1Y
+1.7%
6M
-4.4%
1M
+9.7%
1W
+9.7%
AVN
Avanos Medical, Inc.
Peer
5Y
-72.6%
3Y
-56.0%
1Y
-17.1%
6M
+9.0%
1M
+14.8%
1W
+6.1%
OCG
Ocugen, Inc.
Peer
5Y
-66.3%
3Y
+137.8%
1Y
+179.0%
6M
+16.8%
1M
-16.3%
1W
+4.8%
RIG
Rigel Pharmaceuticals, Inc.
Peer
5Y
-6.8%
3Y
+165.8%
1Y
+92.5%
6M
+16.1%
1M
+27.5%
1W
+11.1%
ESP
Esperion Therapeutics, Inc.
Peer
5Y
-91.3%
3Y
+70.1%
1Y
+119.8%
6M
-9.3%
1M
-23.4%
1W
-10.7%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-36.94
PEG Ratio
N/A
P/B Ratio
3.46
P/S Ratio
3.1
EV/Revenue
2.54
EV/EBITDA
-30.87
Market Cap
$622.29M
Profitability
Profit margins and return metrics
Profit Margin
-9.41%
Operating Margin
-4.37%
Gross Margin
79.57%
ROE
-10.97%
ROA
-5.95%
Growth
Revenue and earnings growth rates
Revenue Growth
+15.0%
Earnings Growth
N/A
Q/Q Revenue Growth
+14.99%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.21
Low debt
Current Ratio
8.55
Strong
Quick Ratio
7.05
Excellent
Cash/Share
$3.35
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.1B
Gross Margin
79.0%
Op. Margin
-4.4%
Net Margin
-2.9%
Total Assets
$0.2B
Liabilities
$0.1B
Equity
$0.2B
Debt/Equity
0.34x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
25%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-04
$N/A
2026-02-23
$-0.04
+68.1% surprise
2025-11-10
$-0.11
+33.3% surprise
2025-08-04
$-0.14
+21.1% surprise
Healthcare Sector Comparison
Comparing SIBN against 447 companies in the Healthcare sector
(26 bullish, 140 neutral, 281 bearish)
Return on Equity (ROE)
-10.97%
This Stock
vs
-97.42%
Sector Avg
-88.7%
(Below Avg)
Profit Margin
-9.41%
This Stock
vs
-14.95%
Sector Avg
-37.1%
(Weaker)
Debt to Equity
0.21
This Stock
vs
3.06
Sector Avg
-93.2%
(Less Debt)
Revenue Growth
15.0%
This Stock
vs
147.85%
Sector Avg
-89.9%
(Slower)
Current Ratio
8.55
This Stock
vs
4.68
Sector Avg
+82.8%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
SIBN
SI-BONE, Inc.
|
NEUTRAL | $622.29M | - | -11.0% | -9.4% | $14.09 | |
|
AVNS
Avanos Medical, Inc.
|
BEARISH | $607.62M | - | -46.7% | -67.0% | $13.09 | Compare |
|
OCGN
Ocugen, Inc.
|
BEARISH | $639.4M | - | -776.9% | -% | $1.95 | Compare |
|
RIGL
Rigel Pharmaceuticals, Inc.
|
BULLISH | $599.31M | 1.66 | 185.9% | 124.7% | $32.43 | Compare |
|
ESPR
Esperion Therapeutics, Inc.
|
NEUTRAL | $598.37M | - | -% | -5.6% | $2.33 | Compare |
SIBN
SI-BONE, Inc.
NEUTRAL
Mkt Cap
$622M
P/E
-
ROE
-11.0%
Price
$14.09
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-07 | HINCKLEY GREGORY K | Director | Option Exercise | 3,085 | $18,325 |
| 2026-04-02 | PISETSKY MICHAEL A | Officer | Sale | 3,134 | $40,466 |
| 2026-04-02 | MAHESHWARI ANSHUL | Chief Financial Officer | Sale | 3,318 | $42,708 |
| 2026-03-12 | NISHIMURA MIKA | Director | Sale | 4,100 | $56,700 |
| 2026-02-17 | PISETSKY MICHAEL A | Officer | Sale | 20,756 | $318,642 |
| 2026-02-17 | MAHESHWARI ANSHUL | Chief Financial Officer | Sale | 21,528 | $330,982 |
| 2026-02-17 | FRANCIS LAURA A. | Chief Executive Officer | Sale | 93,475 | $1,432,122 |
| 2026-02-17 | RECUPERO ANTHONY JOHN | Former | Sale | 21,049 | $324,204 |
| 2026-02-13 | PISETSKY MICHAEL A | Officer | Stock Award | 78,294 | - |
| 2026-02-13 | MAHESHWARI ANSHUL | Chief Financial Officer | Stock Award | 107,992 | - |
| 2026-02-13 | FRANCIS LAURA A. | Chief Executive Officer | Stock Award | 229,481 | - |
| 2026-02-02 | DUNN JEFFREY W | Director | Sale | 337 | $5,532 |
| 2026-01-08 | DUNN JEFFREY W | Director | Sale | 20,000 | $425,506 |
| 2026-01-02 | PISETSKY MICHAEL A | Officer | Sale | 3,460 | $67,896 |
| 2026-01-02 | MAHESHWARI ANSHUL | Chief Financial Officer | Sale | 5,229 | $102,711 |
HINCKLEY GREGORY K
Director
2026-04-07
3,085 shares
·
$18,325
PISETSKY MICHAEL A
Officer
2026-04-02
3,134 shares
·
$40,466
MAHESHWARI ANSHUL
Chief Financial Officer
2026-04-02
3,318 shares
·
$42,708
NISHIMURA MIKA
Director
2026-03-12
4,100 shares
·
$56,700
PISETSKY MICHAEL A
Officer
2026-02-17
20,756 shares
·
$318,642
MAHESHWARI ANSHUL
Chief Financial Officer
2026-02-17
21,528 shares
·
$330,982
FRANCIS LAURA A.
Chief Executive Officer
2026-02-17
93,475 shares
·
$1,432,122
RECUPERO ANTHONY JOHN
Former
2026-02-17
21,049 shares
·
$324,204
PISETSKY MICHAEL A
Officer
2026-02-13
78,294 shares
MAHESHWARI ANSHUL
Chief Financial Officer
2026-02-13
107,992 shares
FRANCIS LAURA A.
Chief Executive Officer
2026-02-13
229,481 shares
DUNN JEFFREY W
Director
2026-02-02
337 shares
·
$5,532
DUNN JEFFREY W
Director
2026-01-08
20,000 shares
·
$425,506
PISETSKY MICHAEL A
Officer
2026-01-02
3,460 shares
·
$67,896
MAHESHWARI ANSHUL
Chief Financial Officer
2026-01-02
5,229 shares
·
$102,711
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
10-K
8-K
10-Q
8-K
10-Q
8-K
10-Q
8-K
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
8 analysts
Truist Securities
2026-04-15
Buy
Buy
TD Cowen
2026-02-24
Buy
Buy
Truist Securities
2026-02-24
Buy
Buy
TD Cowen
2026-01-27
Buy
Truist Securities
2025-12-18
Buy
Buy
Canaccord Genuity
2025-12-17
Buy
Buy
Needham
2025-12-16
Buy
Buy
Morgan Stanley
2025-12-02
Overweight
Overweight
Past News Coverage
Recent headlines mentioning SIBN from our newsroom.
Newest → oldest
No matching news yet.